Hansa Biopharma interim report Jan-Mar 2021
First commercial sales of Idefirix
® recorded in Q1; New preclinical collaboration with argenx; Encouraging three-year follow-up data in kidney transplantation
Hansa Biopharma AB
Publicerad: 22 april 2021, 08:00
Lund, Sweden April 22, 2021 Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January – March, 2021
.
First commercial sales of Idefirix
® recorded in Q1 2021 following treatment of the first patients. Commercial launch activities in early launch countries continue to be carried out as planned. National level reimbursement application processes underway and decisions by authorities in the first markets expected from mid-year and onwards.
Hansa Biopharma interim report Jan-Mar 2021 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.